Exo Biologics

4 trials 2 recruiting Commercial sponsor Merged from 4 name variants

Filter these 4 trials by condition, phase, country and more.

Open in Search →

4 Registered trials

2 Recruiting

1 Completed trials

5 Countries active

4 Unique IMPs

100% Results reported

Phase I/II

Phase I

Phase I (FiH)

Phase I/II: 1 Phase I: 1 Phase I (FiH): 2

100%

1 of 1 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Bronchopulmonary dysplasia 1 Krabbe's disease 1 Inflammation 1

Top IMPs

ADENO-ASSOCIATED VIRUS SEROTYPE RH10 CONTAINING THE HUMAN GALC GENE 1 ALLOGENEIC UMBILICAL CORD MESENCHYMAL CELLS-DERIVED EXTRACELLULAR VESICLES 1 MB-001 1 SODIUM CHLORIDE 1

All trials

4 total

A Phase 1/2 Clinical Study of Intravenous Gene Transfer with an AAVrh10 Vector Expressing GALC in Krabbe Subjects Receiving Hematopoietic St… Not authorised

2023-504900-28-00 Phase I (FiH) 1 country ADENO-ASSOCIATED VIRUS SEROTYPE RH10 CONTAINING THE HUMAN GALC GENE
A Study to Test a New Drug in Adults With Moderate to Severe Ulcerative Colitis Recruiting

2025-524719-35-00 Phase I/II 1 country MB-001
Safety and effect of mesenchymal derived Extracellular Vesicles in the prevention of Bronchopulmonary Dysplasia in extremely preterm newborn… Recruiting

2022-500293-34-01 Phase I (FiH) 2 countries ALLOGENEIC UMBILICAL CORD MESENCHYMAL CELLS-DERIVED EXTRACELLULAR VESICLES; SODI…
A FIRST-IN-HUMAN PHASE I TRIAL OF OX118 IN HEALTHY VOLUNTEERS Ended

2024-515378-28-00 Phase I 1 country

Showing 1–4 of 4 trials

← All sponsors A–Z